掲載種別：研究論文（学術雑誌）   出版者・発行元：American Society of Clinical Oncology (ASCO)  

640

Background: Recently, MRI-based assessments of bladder cancer using VI-RADS, radiomics, and deep learning models have been widely reported. However, it has not been known whether MRI-based approaches can comprehensively predict detailed pathological findings and survival outcomes. This study aimed to evaluate a multimodal approach integrating VI-RADS, radiomics, and deep learning features for predicting both pathology and survival outcomes. Methods: We retrospectively analyzed 106 patients with bladder cancer who underwent MRI and TURBT between August 2021 and July 2023. VI-RADS were assessed by two urologists. Tumors were manually segmented in 3D slicer, and radiomic features were extracted with PyRadiomics. Deep learning–derived features were obtained from cropped tumor images using EfficientNet-B7. Detailed pathological outcomes were modeled after feature selection with LASSO regression and cross-validation. For survival analysis, OS and PFS at 3 years were evaluated. Risk scores were derived from LASSO-selected features, and cutoff values were determined by ROC analysis to stratify patients into risk groups. Results: The multimodal approach showed favorable predictive performance. In this study, features selected by LASSO consisted of 85% from EfficientNet, 10% from VI-RADS, and 5% from radiomics. For pathological findings, neural boosting achieved high accuracy with AUCs of 0.995 for MIBC, 0.970 for T stage, 0.965 for high grade, 0.983 for necrosis, 0.891 for variant histology, and 0.917 for CIS. For survival outcomes, the risk score achieved AUCs of 0.835 for 3-year OS and 0.926 for 3-year PFS. Kaplan–Meier analysis demonstrated significantly poorer overall survival (HR = 13.99, 95% CI 3.84–50.58) and progression-free survival (HR = 18.79, 95% CI 4.11–85.79) in the high-risk group compared with the low-risk group. Conclusions: Integration of MRI-derived VI-RADS, radiomics, and deep learning features enables accurate prediction of pathology and prognosis in bladder cancer without additional clinical factors. This MRI-based multimodal risk score may support individualized patient stratification and treatment decision-making.

DOI： 10.1200/jco.2026.44.7_suppl.640

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier BV  

DOI： 10.1016/s0302-2838(26)00926-7

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Springer Science and Business Media LLC  

Abstract

Machine learning has shown promise in medical image classification. However, its generalizability remains challenging. Here, we show that data-efficient pre-surgical prognostication of prostate cancer from biopsy specimens is enabled by versatile feature extraction from whole-mount histopathology and a clinically informed intermediate reasoning step. With data from multiple institutions, our pipeline resolved dual-domain shifts across specimen types and institutions and achieved consistent external validation, reinforced by comprehensive analyses of generalizability. This highlights the robustness of our prognostic approach when compared to the Gleason grading system. We establish an equitable, interpretable, and clinically applicable framework, supporting actionable decisions for prognosis and treatment planning, even in limited real-world clinical environments.

DOI： 10.1038/s41746-025-02193-x

PubMed

researchmap

その他リンク： https://www.nature.com/articles/s41746-025-02193-x

掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier BV  

DOI： 10.1016/j.esmorw.2025.100646

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：MDPI AG  

Background/Objectives: The Vesical Imaging-Reporting and Data System (VI-RADS) provides high diagnostic accuracy for muscle-invasive bladder cancer; however, its prognostic value remains limited. We propose serum cytokeratin 19 fragment (CYFRA 21-1) and tumor contact length (TCL) as complementary prognostic factors. We aimed to construct a composite risk score integrating VI-RADS, CYFRA 21-1, and TCL for prognostic stratification. Methods: We retrospectively analyzed data from 101 patients with bladder cancer (BC) who underwent transurethral resection of bladder tumor (TURBT), magnetic resonance imaging, and postoperative serum CYFRA 21-1 measurement. For each factor, cut-off values were determined using receiver operating characteristic (ROC) analysis; meeting each threshold contributed one point (score range, 0–3). Overall survival (OS) was assessed using Kaplan–Meier and Cox regression analyses. Results: ROC analysis identified cut-offs of VI-RADS ≥ 3 (area under the curve [AUC] 0.779), TCL ≥ 40 mm (AUC 0.817), and CYFRA 21-1 ≥ 2.1 ng/mL (AUC 0.875). Based on these, patients were stratified into low- (0–1, n = 81), intermediate- (2, n = 12), and high-risk (3, n = 8) groups with 3-year OS rates of 95.1%, 75.0%, and 25.0%, respectively (p < 0.001). In univariate Cox regression, all factors significantly predicted poor OS: VI-RADS ≥ 3 (hazard ratio [HR], 6.51; p = 0.015), TCL ≥ 40 mm (HR, 8.36; p < 0.001), and CYFRA 21-1 ≥ 2.1 ng/mL (HR, 14.02; p < 0.001). In multivariate analysis, only CYFRA 21-1 remained independently significant (HR, 11.80; p < 0.001). Conclusions: A composite risk score combining VI-RADS, TCL, and CYFRA 21-1 effectively stratified patients with BC into distinct groups using minimally invasive, peri-TURBT assessments. Prospective multicenter validation is warranted.

DOI： 10.3390/diagnostics15232968

PubMed

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier BV  

DOI： 10.1016/s2666-1683(25)01701-x

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier BV  

DOI： 10.1016/s2666-1683(25)01539-3

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier BV  

DOI： 10.1016/s2666-1683(25)01737-9

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier BV  

DOI： 10.1016/s2666-1683(25)01558-7

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: To evaluate the primary resistance factors to enfortumab vedotin (EV) monotherapy by comparing treatment outcomes between the early progressive disease (EPD) group and non-EPD group. METHODS: We retrospectively analyzed 121 patients with advanced urothelial carcinoma who received EV monotherapy across five institutions between 2019 and 2024. The patients were categorized into the EPD group (n = 34), defined by radiologically confirmed progressive disease within 3 months of EV initiation, and the non-EPD group (n = 87). The clinical parameters and oncological outcomes were compared between groups. The emergence of new metastatic lesions was defined as the detection of metastases in organs not previously identified as metastatic sites at baseline, during prior chemotherapy or immune checkpoint inhibitors (ICIs) before the initiation of EV. RESULTS: The median overall survival was significantly shorter in the EPD group than in the non-EPD group (6.5 vs. 19.9 months, p < 0.001). The EPD group had a significantly higher incidence of new metastatic lesions and a lower prevalence of normal Hb levels. Multivariate analysis identified low Hb and the presence of new metastatic lesions as independent predictors of EPD. Among patients with new metastases in the EPD group, an average of 74% of lesions emerged during ICI treatment and 75% involved multiple foci. Notably, more than 50% of these new lesions showed progression at the same sites following EV therapy. CONCLUSIONS: Patients with low hemoglobin levels and new metastatic lesions before EV treatment may be at increased risk for EPD. For these patients, alternative treatment strategies should be considered before initiating EV.

DOI： 10.1007/s10147-025-02822-1

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2025&ichushi_jid=J07650&link_issn=&doc_id=20250910380002&doc_link_id=10.11302%2Fjserjje.38.2_178&url=https%3A%2F%2Fdoi.org%2F10.11302%2Fjserjje.38.2_178&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：MDPI AG  

We investigated the clinical significance of positive surgical margins (PSMs) in index tumors following radical prostatectomy (RP), with particular attention to the tumor’s zonal origin. Among 1148 patients with localized prostate cancer who underwent RPs, 973 were included after excluding those who received perioperative therapy or had incomplete data. Index tumors were categorized by zonal origin: transition zone, peripheral zone, or central zone (CZ). Overall, PSMs were observed in 26.4% of index tumors. Although CZ index tumors were relatively uncommon (6.5%), they exhibited the highest PSM rate (42.9%) and showed the most aggressive pathological features. The 5-year biochemical recurrence (BCR)-free survival rate was significantly lower in patients with PSMs in index tumors than in those with negative surgical margins (45.6% vs. 86.8%, p &lt; 0.0001). Notably, patients with PSMs in CZ index tumors had the worst outcomes, with a 5-year BCR-free survival rate of 22.0%. Multivariate analysis identified PSMs in index tumors as an independent predictor of BCR (HR: 3.4; 95% CI: 2.5–4.5), with a similar trend observed in early recurrence. These findings highlight the prognostic significance of PSMs in index tumors during RP, especially in CZ tumors, and emphasize the importance of securing local control in these cases.

DOI： 10.3390/curroncol32080445

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：MDPI AG  

The Vesical Imaging Reporting and Data System (VI-RADS) is used to detect muscle-invasive bladder cancer, with emerging prognostic implications. Integrating imaging parameters with molecular biomarkers may improve risk stratification in bladder cancer. This study evaluated whether combining VI-RADS scores with serum cytokeratin fragment 19 (CYFRA 21-1) levels—a clinically relevant biomarker for bladder cancer—could improve overall survival (OS) prediction. We retrospectively analyzed 134 patients who underwent transurethral resection of bladder tumors, magnetic resonance imaging, and postoperative serum CYFRA 21-1 measurements. In total, 15 cancer-specific deaths were observed during follow-up. Receiver operating characteristic curve analysis identified optimal prognostic cut-off values: VI-RADS score ≥ 4 and CYFRA 21-1 level ≥ 1.8 ng/mL. The 1-, 2-, and 3-year OS in patients with both high VI-RADS scores and CYFRA 21-1 levels were 42.9%, 16.7%, and 8.3%, respectively, significantly lower than those in other groups (p &lt; 0.001, 0.002, and 0.003, respectively). Multivariate Cox proportional hazards analysis demonstrated that such patients had the poorest OS (hazard ratio: 7.51; p = 0.002). This suggests that combining VI-RADS and CYFRA 21-1 improves prognostic accuracy in bladder cancer, demonstrating potential clinical utility by informing individualized treatment strategies; however, limitations include the retrospective study design and absence of external validation.

DOI： 10.3390/curroncol32080415

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

ABSTRACT

Background

We investigated the clinical and economic outcomes of robot‐assisted radical prostatectomy (RARP) using the hinotori surgical system (H‐RARP).

Methods

The analysis was conducted on 76 and 68 patients who underwent RARP using the da Vinci surgical system (D‐RARP) and H‐RARP, respectively. Safety, oncological, and functional outcomes were compared between H‐RARP and D‐RARP. Risk factors influencing medical costs in RARP were identified via linear regression analysis.

Results

Except for longer operative time in H‐RARP, clinical outcomes were comparable. The median medical costs per case were $12,426.8 for D‐RARP and $12,548.9 for H‐RARP. Operative time (coefficient: 0.0002, p &lt; 0.001), pathological T stage (coefficient: 0.023, p = 0.030), and postoperative hospital stay (coefficient: 0.028, p &lt; 0.001) were significant factors affecting medical costs; in contrast, the type of robot‐assisted surgical system was not a significant factor.

Conclusions

H‐RARP offers clinical outcomes comparable to those of D‐RARP while maintaining equivalent medical costs.

DOI： 10.1002/rcs.70084

PubMed

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Ovid Technologies (Wolters Kluwer Health)  

DOI： 10.1097/01.ju.0001110136.41716.b7.14

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Medical Association of Nippon Medical School  

BACKGROUND: Prostate cancer (PCa) significantly contributes to male cancer mortality. Triplet therapy shows promise for metastatic castration-sensitive prostate cancer (mCSPC), but real-world data are limited. This study aimed to evaluate the clinical outcomes of triplet therapy in real-world patients with mCSPC at an academic hospital in Japan. METHODS: We retrospectively analyzed the efficacy and safety of triplet therapy, comprising androgen deprivation therapy, docetaxel, and darolutamide, in patients with mCSPC at Nippon Medical School Hospital. Clinical outcomes, adverse events (AEs), prostate-specific antigen (PSA) responses, and progression to castration-resistant prostate cancer were assessed. RESULTS: Between January 2023 and June 2024, we identified 14 Japanese patients with mCSPC who received triplet therapy. All patients presented with synchronous high-volume metastases as defined by the CHAARTED criteria. The median follow-up period was 7.9 months. In terms of efficacy, all 14 patients achieved PSA reduction of > 90%, while 13 of them achieved reductions of > 99%. AEs were reported in all patients, with grade 3 or higher AEs occurring in 10 patients. One patient permanently discontinued treatment and 4 patients temporarily interrupted therapy due to AEs. During follow-up, biochemical progression was observed in 2 patients and radiological progression in 2 patients. Subsequent therapies were selected based on each patient's clinicopathological and genetic characteristics, with considerable variability in treatment approaches following progression. CONCLUSIONS: While PSA responses were favorable and tolerability was generally high, progression patterns and subsequent therapies varied widely, highlighting the need for close monitoring and individualized treatment in patients with mCSPC receiving triplet therapy.

DOI： 10.1272/jnms.jnms.2025_92-212

PubMed

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier BV  

DOI： 10.1016/j.eururo.2025.09.2832

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：American Society of Clinical Oncology (ASCO)  

690

Background: VI-RADS is widely used to identify muscle-invasive bladder cancer (MIBC). However, it is not known whether structural category (SC; VI-RADS based on T2-weighted images) alone is useful in diagnosing clinicopathological features and prognosis of bladder cancer. This study investigates the diagnostic performance of SC in the detection of MIBC. We also measured tumour contact length (TCL), difference in signal intensity ratio (dSIR) and coefficient of variation (CV) within the tumour on T2WI. We evaluated whether these factors could improve the diagnostic performance of SC for MIBC and explored the correlation between these morphological features and clinicopathological characteristics and prognosis. Methods: Between August 2018 and July 2023, we performed 587 transurethral resections of bladder tumours. This study includes 236 patients who underwent preoperative MRI. We first evaluated the diagnostic performance of VI-RADS and SC for MIBC. TCL, dSIR and CV were measured on T2WI. The dSIR was defined as the difference between the signal intensity (SI) of the tumour and that of the underlying muscle layer, divided by the SI of the normal muscle layer. The CV was calculated as the standard deviation of the SI within the tumour divided by the mean SI. All patients were divided into high and low SC groups and the relationship between MIBC and TCL, dSIR and CV was examined. Cut-off values for the diagnosis of MIBC and overall survival (OS) were calculated based on ROC curves for the most correlated factors in each group, which were added to the SC score to evaluate the diagnostic value. We also examined the correlation between each factor and pathological findings. Results: The diagnostic performance of VI-RADS with a cut-off score of 4 was an AUC of 0.888. Meanwhile, the diagnostic performance of SC with a cut-off score of 4 was AUC of 0.885. The association between MIBC and each factor was compared in the SC≥4 and SC≤3 groups. In the SC≥4, multivariate analysis showed significant differences in dSIR (p&lt;0.001). In the SC≤3, multivariate analysis showed TCL is significantly longer in MIBC (p&lt;0.001). The diagnostic performance was an AUC of 0.912 for suspected MIBC with SC≥4 and dSIR&lt;1.03 and SC≤3 and TCL≥36mm. In pathological features, TCL is significantly longer in high-grade (p=0.018), necrosis(p&lt;0.001), variant(p=0.002), lymph node metastasis (p&lt;0.001) and organ metastasis (p&lt;0.035). Univariate COX analysis showed that SC≥4 was risk factors for OS (HR = 2.15, P = 0.031). In the SC≥4, patients with TCL≥40 mm had worse OS (HR = 3.06, P &lt; 0.015). In the SC≤3, patients with TCL≥31 mm had worse OS (HR = 10.59, P &lt; 0.001). Conclusions: The present study showed that SC combined with dSIR and TCL has good diagnostic performance for MIBC. We also found that TCL correlates with high-grade tumor, necrosis, and variant histology. The combination of SC and TCL effectively predicts OS in bladder cancer.

DOI： 10.1200/jco.2025.43.5_suppl.690

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Current guidelines lack recommendations for serum tumor markers in patients with upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU). This study assessed the potential of the postoperative serum C-terminus of cytokeratin 19 (CYFRA21-1, CYFRA) level, hereafter referred to as poCY, as a predictor of early progression in patients treated with RNU. METHODS: Overall, 117 patients were categorized into the high group (HG) or low group (LG) based on a poCY cutoff level of 3.5 ng/mL after excluding those who did not meet the inclusion criteria. Kaplan-Meier curves and log-rank tests were used to measure cancer-specific survival (CSS) and progression-free survival (PFS) rates. Multivariate analysis was performed using the Cox proportional hazards model. RESULTS: During a median follow-up of 34 months, the 5-year CSS and PFS rates were 79% and 66%, respectively. The HG had a significantly worse CSS and 2-year PFS than the LG. Multivariate analyses identified poCY and lymph node involvement (LNI) as independent prognostic factors. Regarding the 2-year PFS, poCY, LNI, and resection margin status (RM) emerged as independent prognostic factors. CONCLUSIONS: poCY, LNI, and RM predicted early progression following RNU in patients with UTUC. Patients with elevated poCY may benefit from adjuvant chemotherapy, irrespective of their pathological findings.

DOI： 10.1272/jnms.JNMS.2025_92-404

PubMed

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier BV  

DOI： 10.1016/j.annonc.2024.10.371

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：MDPI AG  

Prostate cancer (PCa) is a clinically heterogeneous disease. Predicting clinically significant PCa with low–intermediate prostate-specific antigen (PSA), which often includes aggressive cancers, is imperative. This study evaluated the predictive accuracy of deep learning analysis using multimodal medical data focused on clinically significant PCa in patients with PSA ≤ 20 ng/mL. Our cohort study included 178 consecutive patients who underwent ultrasound-guided prostate biopsy. Deep learning analyses were applied to predict clinically significant PCa. We generated receiver operating characteristic curves and calculated the corresponding area under the curve (AUC) to assess the prediction. The AUC of the integrated medical data using our multimodal deep learning approach was 0.878 (95% confidence interval [CI]: 0.772–0.984) in all patients without PSA restriction. Despite the reduced predictive ability of PSA when restricted to PSA ≤ 20 ng/mL (n = 122), the AUC was 0.862 (95% CI: 0.723–1.000), complemented by imaging data. In addition, we assessed clinical presentations and images belonging to representative false-negative and false-positive cases. Our multimodal deep learning approach assists physicians in determining treatment strategies by predicting clinically significant PCa in patients with PSA ≤ 20 ng/mL before biopsy, contributing to personalized medical workflows for PCa management.

DOI： 10.3390/curroncol31110530

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Enfortumab vedotin (EV) was approved for patients with metastatic urothelial carcinoma (mUC) who progressed after anticancer therapy on September 2021 in Japan. The association between the occurrence of EV-related side effects and clinical outcome remains to be elucidated. METHODS: We identified 97 mUC patients treated with EV therapy at our five institutions from the date of approval to March 2023. The median follow-up period was 7.0 months. We retrospectively analyzed the efficacy and safety of EV. RESULTS: The median age of the patients was 71 years old, 39% had PS of 1 or more, and 56.7% had primary tumor in upper urinary tract. Overall response rate (ORR) to EV therapy, median progression-free survival (PFS), and overall survival (OS) were 43.3%, 7.52 months, and 12.78 months, respectively. Any grade of treatment-related skin disorder, dysgeusia, peripheral neuropathy, gastrointestinal disorder, and hyperglycemia occurred in 61 (62.9%), 36 (37.1%), 34 (35.1%), 29 (29.9%), and 18 (18.6%) patients, respectively. The patients with EV-associated peripheral neuropathy had significantly higher ORR (58.8% vs. 34.9%, P = .032) and longer median PFS (8.05 vs. 6.31 months, P = .017) and OS (not reached vs. 11.57 months, P = .008, respectively) than those without. The occurrence of peripheral neuropathy after EV treatment and the presence of peritoneal dissemination were factors independently associated with PFS (hazard ratio = 0.46, P = .008 and hazard raito = 3.83, P = .004, respectively) and OS (hazard ratio = 0.30, P = .005 and hazard raito = 4.53, P = .002, respectively). CONCLUSIONS: The occurrence of EV-related peripheral neuropathy might be associated with the efficacy of EV therapy in mUC patients.

DOI： 10.1093/jjco/hyae082

PubMed

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier BV  

DOI： 10.1016/s2666-1683(24)01130-3

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: The presence of collateral vessels (CVs) on contrast-enhanced computed tomography is a poor prognostic factor in renal cell carcinoma (RCC), but its value in small RCC (sRCC; < 4 cm) remains unknown. In this study, we investigated whether presence of CVs is a predictor of high potential for metastasis in sRCC. METHODS: We retrospectively reviewed clinical and imaging data of patients with pathologically confirmed sRCC evaluated at our institution between 2011 and 2021. All sRCCs were pathologically diagnosed by biopsy, metastasectomy, partial nephrectomy, or radical nephrectomy. CVs were defined as blood vessels of any diameter connecting the tumor with the surrounding perirenal tissues on contrast-enhanced computed tomography. The rate of metastasis-free survival (MFS), defined as the time from pathological diagnosis to confirmed metastasis, was compared among patients without CVs, those with one CV, and those with two or more CVs. RESULTS: Of 141 patients, 4 (2.8%) had metastatic sRCC at initial diagnosis. In the 137 patients with nonmetastatic sRCC, the diagnosis was pathologically confirmed following radical surgery. The median follow-up period from pathological diagnosis was 73.9 months, and the overall 5-year MFS was 93.5%. The 5-year MFS was significantly poorer in patients with two or more CVs than in those with one CV (63.8% vs. 96.3%; p = 0.0003) and those without CVs (63.8% vs. 100%; p < 0.0001). CONCLUSIONS: sRCCs with two or more CVs might have high potential for metastasis. Conversely, sRCCs without CVs might not be aggressive and be suitable for active surveillance.

DOI： 10.1007/s12672-024-01409-y

PubMed

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Elsevier BV  

DOI： 10.1016/j.annonc.2024.08.2090

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Prolonged laparoscopic nephroureterectomy (LNU) for upper tract urothelial cancer (UTUC) can increase the frequency of intravesical recurrence after surgery. Therefore, it is important for urological surgeons to have knowledge on preoperative risk factors for prolonged LNU. However, few studies have investigated the risk factors for prolonged LNU. We hypothesized that the quantity of perirenal fat affects the pneumoretroperitoneum time (PRT) of retroperitoneal LNU (rLNU). This study aimed to investigate the preoperative risk factors for prolonged PRT during rLNU. METHODS: We reviewed the data of 115 patients who underwent rLNU for UTUC between 2013 and 2021. The perirenal fat thickness (PFT) observed on preoperative computed tomography (CT) images was used to evaluate the perinephric fat quantity. Preoperative risk factors for PRT during rLNU were analyzed using logistic regression models. The cutoff value for PRT was determined based on the median time.The cutoff values for fat-related factors influencing PRT were defined according to receiver operating characteristic curve analysis. RESULTS: The median PRT for rLNU was 182 min (interquartile range, 155-230 min). The cutoff values of posterior, lateral, and anterior PFTs were 15 mm, 24 mm, and 6 mm, respectively. Multivariate analysis revealed that a posterior PFT ≥ 15 mm (odds ratio [OR], 2.72; 95% confidence interval, 1.04-7.08; p = 0.0410) was an independent risk factor for prolonged PRT. CONCLUSIONS: Thick posterior PFT is a preoperative risk factor for prolonged PRT during rLNU. For patients with UTUC and thick posterior PFT, surgeons should develop optimal surgical strategies, including the selecting an expert surgeon as a primary surgeon and the selecting transperitoneal approach to surgery or open surgery.

DOI： 10.1186/s12894-024-01538-0

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Springer Science and Business Media LLC  

Abstract

Background

Index tumors are the most aggressive tumors of the prostate. However, their clinical significance remains unclear. This study aimed to assess the incidence of index tumor location according to the zonal origin and whether these locations affect the prognosis after radical prostatectomy in patients with negative surgical margins.

Methods

This single-centered, retrospective study evaluated 1,109 consecutive patients who underwent radical prostatectomies. An index tumor was defined as the largest tumor in the prostate gland. We detected these locations based on McNeal's zonal origin using whole-mount sections. Biochemical recurrence (BCR) free survival curves were generated using the Kaplan–Meier method. Univariate and multivariate analyses using the Cox proportional hazards model were performed to determine the predictive factors for early BCR (within 1-year).

Results

A total of 621 patients with negative surgical margins who did not receive adjuvant therapy were included in this study. The index tumor were located in the transitional zone in 191 patients (30.8%), the peripheral zone in 399 patients (64.3%), and the central zone in 31 patients (5.0%). In total, 22 of 621 patients (3.5%) experienced early BCR and 70 patients (11.2%) experienced overall BCR at a median follow-up of 61.7 months. According to the index tumor location, the early BCR-free rates were 99.5%, 95.7 %, and 83.3% in the transitional, peripheral, and central zones, respectively. On multivariate analysis, the index tumor in the central zone was an independent predictor of early BCR with negative surgical margins following radical prostatectomy, followed by prostatectomy pathological grade, index tumor in the peripheral zone, and high prostate-specific antigen level.

Conclusions

We assessed the significance of index tumor location in patients with negative surgical margins following radical prostatectomy. Index tumors located in the central zone, although infrequent, were the strongest predictive factors for early BCR. Our results may allow urologists and patients to reconsider the therapeutic strategies for prostate cancer.

DOI： 10.1186/s12894-024-01499-4

PubMed

researchmap

その他リンク： https://link.springer.com/article/10.1186/s12894-024-01499-4/fulltext.html

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：MDPI AG  

In patients with high-risk prostate cancer (HRPC) after radical prostatectomy (RP), biochemical recurrence (BCR) increases the risk of distant metastasis. Accordingly, additional prognostic biomarkers are required to identify the subpopulation of patients with HRPC who develop clinical recurrence (CR) after BCR. The objective of this study was to identify biomarkers in formalin-fixed paraffin-embedded (FFPE) RP samples that are prognostic for CR in patients with HRPC who experience BCR after RP (post-RP BCR). First, we performed a preliminary RNA sequencing analysis to comprehensively profile RNA expression in FFPE RP samples obtained from patients with HRPC who developed CR after post-RP BCR and found that many snRNAs were very abundant in preserved FFPE samples. Subsequently, we used quantitative polymerase chain reaction (qPCR) to compare the expression levels of highly abundant snRNAs in FFPE RP samples from patients with HRPC with and without CR after post-RP BCR (21 CR patients and 46 non-CR patients who had more than 5 years of follow-up after BCR). The qPCR analysis revealed that the expression levels of snRNA RNU1-1/1-2 and RNU4-1 were significantly higher in patients with CR than in patients without CR. These snRNAs were significantly correlated with clinical recurrence-free survival (RFS) in patients with HRPC who experienced post-RP BCR. Furthermore, snRNA RNU1-1/1-2 could serve as an independent prognostic factor for clinical RFS in post-RP BCR of HRPC cases where known prognostic factors (e.g., Gleason score) cannot distinguish between CR and non-CR patients. Our findings provide new insights into the involvement of snRNAs in prostate cancer progression.

DOI： 10.3390/cancers16091757

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: The Vesical Imaging Reporting and Data System (VI-RADS) is widely used for predicting muscle-invasive bladder cancer (MIBC). This study aimed to determine the clinicopathological significance of the VI-RADS ≧4 (VI≧4) group. METHODS: Patients who underwent transurethral resections of bladder tumors during the study period and preoperative magnetic resonance imaging were considered. The patients were pathologically diagnosed with urothelial carcinoma (UC). We first compared the results of patients with VI-RADS scores of 3 and 4 to determine the cut-off score for MIBC; thereafter, the patients were divided into the VI≧4 and VI-RADS ≦3 (VI≦3) groups using VI-RADS. The clinicopathological significance of the VI≧4 group was examined retrospectively by comparing the characteristics of each group. RESULTS: In total, 121 cases were examined, of which 28 were pathologically diagnosed with MIBC. Of the 28 MIBC cases, three (10.7%) had a VI-RADS score of ≦3, and 25 (89.3%) had a VI-RADS score of ≧4. Of the 93 NMIBC cases, 86 (92.5%) had a VI-RADS score of ≦3, and seven (7.5%) had a VI-RADS score of ≧4. The diagnostic performance of the VI-RADS with a cut-off score of 4 was 89.3% for sensitivity, 92.5% for specificity, and an area under the curve (AUC) of 0.91. Contrastingly, for a cut-off score of 3, the sensitivity was 89.3%, specificity was 62.0%, and AUC was 0.72. A VI-RADS score of ≥ 4 could predict MIBC. In the VI≧4 group, 30 of 32 (93.8%) patients had high-grade tumors. The VI≧4 group had significantly more high-grade bladder cancers than the VI≦3 group (p < 0.001 OR = 31.77 95%CI:8.47-1119.07). In addition, the VI≧4 group had more tumor necrosis (VI≧4 vs VI≦3, p < 0.001 OR = 7.46 95%CI:2.61-21.34) and more UC variant cases (VI≧4 vs VI≦3, p = 0.034 OR = 3.28 95%CI:1.05-10.25) than the VI≦3 group. CONCLUSIONS: This study suggests that VI-RADS has a high diagnostic performance in predicting MIBC and that VI-RADS could diagnose high-grade tumors, necrosis, and UC variants.

DOI： 10.1186/s12894-024-01452-5

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

This study presents the enfortumab vedotin (EV) treatment analysis at our institution. We retrospectively analyzed patients with metastatic urothelial cancer (mUC) treated with EV between January 2021 and October 2023. EV was administered at 1.25 mg/kg on days 1, 8, and 15 in a 28-day cycle. Whole-body computed tomography scans were performed to assess the treatment response. Patient characteristics, treatment histories, response rates, progression-free survival, and adverse events were evaluated. Response rates were determined, and adverse events were recorded. Among the 20 patients, 70% were male and 65% had bladder tumors. Most patients had lung (65%) or lymph node (65%) metastases. The median follow-up was 11.2 months, with 45% of the patients succumbing to the disease. The overall response rate was 55%. The median progression-free and median overall survivals were 10.5 and 12.9 months, respectively. Severe adverse events occurred in 35% of patients. In this real-world study, EV demonstrated promising efficacy and manageable safety profiles in Japanese patients with mUC. The study's results were consistent with previous clinical trials, although a longer follow-up was required. Our findings support EV use as a treatment option for patients with mUC who exhibit disease progression after platinum-based chemotherapy and immune-checkpoint inhibitor therapy.

DOI： 10.3390/curroncol31020056

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: This study aimed to investigate the preoperative risk factors for prolonged operating time in retroperitoneoscopic radical nephrectomy (RRN) for renal cell carcinoma (RCC). METHODS: We retrospectively reviewed patients treated for RRN between January 2015 and December 2021. Clinical data, including radiological findings such as visceral fat area (VFA), subcutaneous fat area (SFA), and posterior perirenal fat thickness (PFT) were collected. The operating time for RRN was analyzed using univariate and multivariate logistic regression analyses. RESULTS: A total of 79 patients were included. The median age was 66 (range: 28-88) years and 48 (60.8%) had right-sided tumors. The median tumor size was 52 (range: 12-100) mm. Median BMI, VFA, SFA, and posterior PFT were 22.9 (range: 16.3-42.2) kg/m2, 102 (range: 14-290) cm2, 124 (range: 33-530) cm2, and 6 (range: 1-35) mm. The median operating time was 248 (range: 140-458) min. Univariate logistic regression analyses revealed that a right tumor (p=0.046), tumor size >7 cm (p=0.010), and posterior PFT >25 mm (p=0.006) were preoperative risk factors for prolonged operating time in RRN. Multivariate logistic regression analyses revealed that a posterior PFT of >25 mm was an independent preoperative risk factor for prolonged operating time for RRN (p=0.008, OR: 7.29, 95% CI: 1.69-31.5). CONCLUSIONS: A posterior PFT >25 mm was an independent preoperative risk factor for the operating time of RRN. In RRN, for patients with a posterior PFT >25 mm, surgeons should develop surgical strategies, including the selection of a transperitoneal approach to surgery, to avoid prolonging the operating time.

DOI： 10.1272/jnms.JNMS.2024_91-407

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Several effective treatment modalities against metastatic castration-resistant prostate cancer (mCRPC) are available; however, an unmet clinical need persists for mCRPC treatment because resistance to these therapies is inevitable. This study aimed to evaluate the status of comprehensive genomic profiling (CGP) and its impact on subsequent treatments for patients with mCRPC at our hospital. METHODS: Between December 2020 and August 2023, we assessed 41 patients with mCRPC who underwent CGP testing at the Nippon Medical School Hospital. The testing comprised FoundationOne® CDx for 30 patients and FoundationOne® Liquid CDx for 11 patients, following the procedures outlined by the Japanese Urological Association. RESULTS: CGP testing was successfully conducted in 40 out of 41 patients (97.6%), which resulted in the identification of 140 actionable genomic alterations. The most common alteration was TP53 in 12 patients (30.0%). Twenty-three patients (57.5%) with druggable gene alterations were identified; 21 were recommended for clinical trials, four for patient-proposed healthcare services, and six for insurance-covered drugs. Consequently, genotype-matched therapy with insurance-covered drugs was administered to five patients (12.5%) with a BRCA2 mutation. Notably, none of the patients underwent clinical or prospective trials based on patient-suggested medical services. CONCLUSIONS: Our results offer insights into the real-world application of CGP testing for patients with mCRPC at a cooperative hospital for cancer genomic medicine in Japan. Thus, urologists require a comprehensive understanding of the current status of CGP testing to enhance mCRPC management.

DOI： 10.1272/jnms.JNMS.2024_91-512

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Renal abscesses require prompt diagnosis and appropriate intervention, as they can be life-threatening. However, diagnosis based solely on clinical findings is often challenging. We present the case of a 69-year-old woman with left renal masses on follow-up computed tomography (CT) after surgery for pT2aN0M0 lung carcinosarcoma. The masses were localized only in the left kidney without suspected metastatic lesions at other sites. The patient was referred to our department for further evaluation and treatment under a diagnosis of suspected metastatic lung carcinosarcoma of the left kidney. On enhanced CT, the left renal masses, the largest of which had a diameter of 40×36 mm had thick irregular walls gradually enhanced by the contrast media and an internal low-attenuation area. The masses showed heterogeneous signal intensity with a pseudocapsule on T2-weighted magnetic resonance imaging. Clinical symptoms such as fever or costovertebral angle tenderness were absent, and blood and urine tests were not sufficiently inflammatory to suggest a renal abscess. Histopathological findings on CT-guided renal biopsy revealed only inflammatory tissue and no tumor cells. However, because lung carcinosarcoma metastatic nodules could not be ruled out, laparoscopic left nephrectomy was performed for a definitive diagnosis and curative intent. The pathological diagnosis was renal abscess without malignant lesions. Here, we present a case of renal abscess mimicking metastatic lesions in a patient with lung carcinosarcoma. Accurately differentiating renal abscesses from metastatic renal tumors before treatment is often difficult. Renal abscess diagnosis should be considered through a comprehensive evaluation of the clinical findings of individual cases.

DOI： 10.1272/jnms.JNMS.2024_91-609

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

Introduction

We report a rare case of marked rectal stenosis due to Douglas' pouch metastasis of renal pelvic urothelial carcinoma successfully treated with enfortumab vedotin.

Case presentation

A 77‐year‐old female presented with difficulty in defecation and abdominal distension. She had received two courses of cisplatin plus gemcitabine followed by four courses of maintenance avelumab for postoperative lymph node metastasis of renal pelvic urothelial carcinoma. KL‐6 levels were elevated, and a computed tomography scan revealed an irregularly shaped large mass occupying Douglas' pouch, with marked rectal stenosis. Metastatic urothelial carcinoma was pathologically diagnosed, and enfortumab vedotin was initiated after colostomy. After 12 courses of enfortumab vedotin, metastatic lesions showed marked shrinkage and KL‐6 levels decreased.

Conclusion

Enfortumab vedotin elicited a remarkable response in treating rectal stenosis due to metastasis of renal pelvic urothelial carcinoma in Douglas' pouch. Furthermore, serum KL‐6 levels were correlated with the severity of metastatic urothelial carcinoma.

DOI： 10.1002/iju5.12645

PubMed

researchmap

DOI： 10.21203/rs.3.rs-3277521/v1

researchmap

記述言語：日本語   出版者・発行元：(一社)日本排尿機能学会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: To investigate the impact of Perirenal fat stranding (PRFS) on progression after radical nephroureterectomy (RNU) for renal pelvic urothelial carcinoma (RPUC) without hydronephrosis and to reveal the pathological findings of PRFS. METHODS: Clinicopathological data, including computed tomography (CT) findings of the ipsilateral PRFS, were collected from the medical records of 56 patients treated with RNU for RPUC without hydronephrosis between 2011 and 2021 at our institution. PRFS on CT was classified as either low or high PRFS. The impact of PRFS on progression-free survival (PFS) after RNU was analyzed using the Kaplan-Meier method and log-rank test. In addition, specimens including sufficient perirenal fat from patients with low and with high PRFS were pathologically analyzed. Immunohistochemical analysis of CD68, CD163, CD3, and CD20 was also performed. RESULTS: Of the 56 patients, 31(55.4%) and 25 (44.6%) patients were classified as having low and high PRFS, respectively. Within a median follow-up of 40.6 months postoperatively, 11 (19.6%) patients showed disease progression. The Kaplan-Meier method and log-rank test revealed that patients with high PRFS had significantly lower PFS rates than those with low PRFS (3-year PFS 69.8% vs 93.3%; p = 0.0393). Pathological analysis revealed that high PRFS specimens (n = 3 patients) contained more fibrous strictures in perirenal fat than low PRFS specimens (n = 3 patients). In addition, M2 macrophages (CD163 +) infiltrating fibrous tissue in perirenal area were observed in all patients with high PRFS group. CONCLUSIONS: PRFS of RPUC without hydronephrosis consists of collagenous fibers with M2 macrophages. The presence of ipsilateral high PRFS might be a preoperative risk factor for progression after RNU for RPUC patients without hydronephrosis. Prospective studies with large cohorts are required in the future.

DOI： 10.1007/s12672-023-00741-z

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：英語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：英語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：英語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：英語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：英語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：英語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：英語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: The optimal treatment modality for locally advanced prostate cancer has not been established. Radiotherapy, hormonal therapy, and combinations of treatments are the main strategies, although the feasibility of radical prostatectomy as a first-line therapy needs to be considered. This retrospective study evaluated the long-term oncological outcome of high-risk prostate cancer treated surgically, using pathological results of the extracted specimen. The relationship between the number of risk factors and the long-term outcome was specifically analyzed. METHODS: High-risk prostate cancer patients who underwent laparoscopic radical prostatectomy at Nippon Medical School from 2000 to 2012 without neoadjuvant therapy of any kind were identified. Risk factors were prostate-specific antigen (PSA) ≥20 ng/ml, pathological ≥T3, and pathological Gleason Score ≥8. Biological failure was defined as PSA ≥0.2 ng/ml. RESULTS: A total of 222 men were identified. One patient had positive lymph node status, and there was a significant difference in surgical margin positivity (52 men, 68.4% vs 56 men 38.4%) between patients with and without biochemical failure. For patients meeting the high risk criteria with a follow-up of up to 133 months, the biochemical recurrence (BCR) -free survival rates at 5 and 10 years were 62.8% and 58.4%, respectively, with a mean time to BCR of 14.0 months. BCR-free survival rates at 5 and 10-year were 73.6% and 71.4%, respectively, with 1 risk factor, 48.7% and 34.6%, respectively, with 2 factors, and 34.5% and 34.5%, respectively, with 3 factors. A single risk factor group had a significantly better outcome than the group with multiple risk factors. The overall survival rate at 5 and 10 years were 94.6% and 93.7%, and the cancer-specific survival rate was 100% at both 5 and 10 years. CONCLUSIONS: Reasonable long-term oncological outcomes can be achieved by surgical treatment for high-risk prostate cancer. The group with 1 risk factor had a significantly better BCR-free rate than the multiple risk factor group.

DOI： 10.1272/jnms.JNMS.2023_90-210

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

INTRODUCTION: We encountered an extremely rare case of a vesicocutaneous fistula due to vesical diverticulitis with stones. CASE PRESENTATION: A 78-year-old male patient presented to our department with complaints of suppurative discharge in the suprapubic area. Computed tomography revealed an enlarged prostate, a vesical diverticulum with stones located on the ventral side, and an aberrant connection between the anterior bladder wall and the external surface of the skin. The patient was diagnosed with a vesicocutaneous fistula due to vesical diverticulitis and was successfully treated with a multidisciplinary approach including vesical diverticulectomy with stone removal and nonviable tissue debridement. The patient continues to receive regular outpatient follow-ups with urinary catheter changes. CONCLUSION: Vesicocutaneous fistulas due to vesical diverticulitis with stones are extremely rare. We should be aware that a vesical diverticulum with stones located on the ventral side might pose a high-risk factor for the formation of a vesicocutaneous fistula in elderly patients.

DOI： 10.1002/iju5.12546

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

The case presented is of a 47-year-old patient with an extravesical pedunculated bladder leiomyoma, which was difficult to distinguish from a retroperitoneal tumor. Preoperatively, it was suspected to be a retroperitoneal tumor and a laparotomy with tumor resection was performed. lntraoperatively, the bladder and tumor were connected by a cord-like tissue. A retrospective review of preoperative images revealed that cord-like tissue, identified intraoperatively, was also present. Bladder leiomyomas can grow as extravesical pedunculated tumors. Therefore, when the continuity between the bladder and tumor is only a cord-like object, the finding ofcontinuity is useful to diagnose with bladder leiomyoma. J. Med. Invest. 70 : 513-515, August, 2023.

DOI： 10.2152/jmi.70.513

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

掲載種別：研究論文（学術雑誌）   出版者・発行元：Medical Association of Nippon Medical School  

DOI： 10.1272/jnms.jnms.2022_89-208

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Springer Science and Business Media LLC  

Abstract

Background

Active surveillance (AS) is one of the treatment methods for patients with small renal masses (SRMs; &lt; 4 cm), including renal cell carcinomas (RCCs). However, some small RCCs may exhibit aggressive neoplastic behaviors and metastasize. Little is known about imaging biomarkers capable of identifying potentially aggressive small RCCs. Contrast-enhanced computed tomography (CECT) often detects collateral vessels arising from neoplastic angiogenesis in RCCs. Therefore, this study aimed to evaluate the association between SRM differential diagnoses and prognoses, and the detection of collateral vessels using CECT.

Methods

A total of 130 consecutive patients with pathologically confirmed non-metastatic SRMs (fat-poor angiomyolipomas [fpAMLs; n = 7] and RCCs [n = 123]) were retrospectively enrolled. Between 2011 and 2019, SRM diagnoses in these patients were confirmed after biopsy or surgical resection. All RCCs were surgically resected. Regardless of diameter, a collateral vessel (CV) was defined as any blood vessel connecting the tumor from around the kidney using CECT. First, we analyzed the role of CV-detection in differentiating between fpAML and RCC. Then, we evaluated the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of RCC diagnosis based on CV-detection using CECT. We also assessed the prognostic value of CV-detection using the Fisher exact test, and Kaplan-Meier method and the log-rank test.

Results

The sensitivity, specificity, PPV, NPV, and accuracy of CV-detection for the diagnosis of small RCCs was 48.5, 45.5, 100, 100, and 9.5% respectively. Five of 123 (4.1%) patients with RCC experienced recurrence. CV-detection using CECT was the only significant factor associated with recurrence (p = 0.0177). Recurrence-free survival (RFS) was significantly lower in patients with CV compared with in those without CV (5-year RFS 92.4% versus 100%, respectively; p = 0.005). In addition, critical review of the CT images revealed the CVs to be continuous with the venous vessels around the kidney.

Conclusions

The detection of CVs using CECT is useful for differentiating between small fpAMLs and RCCs. CV-detection may also be applied as a predictive parameter for small RCCs prone to recurrence after surgical resection. Moreover, AS could be suitable for small RCCs without CVs.

DOI： 10.1186/s12885-022-09971-w

PubMed

researchmap

その他リンク： https://link.springer.com/article/10.1186/s12885-022-09971-w/fulltext.html

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)腎癌研究会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: We evaluated whether the efficacy and safety of transurethral enucleation with bipolar energy (TUEB) is affected by prostate volume (PV) in the treatment of benign prostatic hyperplasia (BPH). METHODS: We retrospectively evaluated 180 patients with symptomatic BPH who underwent TUEB between 2008 and 2015. Efficacy was assessed by perioperative changes in the international prostate symptom score (IPSS), Quality of Life Score (QOLS), maximum flow rate on uroflowmetry (Qmax), and serum prostate-specific antigen level (PSA), which were recorded at 3 months postoperative. Safety was assessed by perioperative incidence of adverse events (AEs). AEs were recorded up to 2 years after surgery. Patients were divided into two groups based on PV: standard group (SG), PV < 80 mL, and large group (LG), PV ≥ 80 mL. RESULTS: A total of 132 (73%) patients were grouped in the SG, whereas 48 (27%) were grouped in the LG. No significant differences were observed in the preoperative parameters of age, IPSS, and QOLS between the two groups. However, the LG had a significantly larger PV and higher serum PSA levels. Regarding surgical outcomes, postoperative changes in IPSS, QOLS, Qmax, serum PSA, serum sodium, and hemoglobin levels did not differ significantly between the groups. However, the LG demonstrated a significantly longer operative time and heavier specimen weight. The rates of early complications, including hyponatremia, and blood transfusion, and late complications after surgery did not differ between the groups. CONCLUSION: This study demonstrated the safety and efficacy of TUEB for BPH therapy regardless of PV.

DOI： 10.1272/jnms.JNMS.2022_89-411

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Because of its low recurrence rate and safety, laparoscopic sacrocolpopexy (LSC) is an increasingly popular treatment for pelvic organ prolapse (POP). Although LSC may improve voiding function, it can also lead to de novo stress urinary incontinence. The exact effects of LSC on voiding function, and the mechanisms responsible, remain unclear. Therefore, in this study we prospectively evaluated the impact of LSC on voiding function by performing a pre- and postoperative urodynamic study of patients with stage 3 or worse POP. METHODS: Urinary status was evaluated before and 3 months after LSC. Pre- and postoperative evaluations included medical history, clinical examination, urodynamic studies, chain cystography, and residual urine volume measurement. Urinary symptoms were assessed using the International Prostate Symptom Score (IPSS) and the Overactive Bladder Symptom Score (OABSS). RESULTS: The nonrecurrence rate at 3 months was 82.3%. All recurrences involved bladder prolapse. In addition to the absence of a significant change in OABSS, the improvement in IPSS suggests that subjective voiding symptoms improved. Although the maximum urinary flow rate did not significantly change, bladder volume at first sensation increased, urinary storage function improved, and residual urine volume decreased. There were no perioperative complications, and no patient reported postoperative difficulty in urination or urinary retention. The retrovesical angle significantly decreased. CONCLUSIONS: The modified LSC in women with POP provides good functional outcomes in terms of IPSS, post-void residual volume (PVR), and urinary storage function.

DOI： 10.1272/jnms.JNMS.2022_89-219

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本薬学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Accurate prostate cancer screening is imperative for reducing the risk of cancer death. Ultrasound imaging, although easy, tends to have low resolution and high inter-observer variability. Here, we show that our integrated machine learning approach enabled the detection of pathological high-grade cancer by the ultrasound procedure. Our study included 772 consecutive patients and 2899 prostate ultrasound images obtained at the Nippon Medical School Hospital. We applied machine learning analyses using ultrasound imaging data and clinical data to detect high-grade prostate cancer. The area under the curve (AUC) using clinical data was 0.691. On the other hand, the AUC when using clinical data and ultrasound imaging data was 0.835 (p = 0.007). Our data-driven ultrasound approach offers an efficient tool to triage patients with high-grade prostate cancers and expands the possibility of ultrasound imaging for the prostate cancer detection pathway.

DOI： 10.1038/s41598-022-04951-3

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Robot-assisted laparoscopic prostatectomy (RALP) for prostate cancer was introduced in 2000 and rapidly gained popularity. The Da Vinci Surgical System? can ensure improved local control of cancer and fewer perioperative complications. However, RALP is performed in the steep-Trendelenburg position (a combination of lithotomy and head-down tilt position/Lloyd-Davies position) to obtain a good surgical view, and as a result, well leg compartment syndrome (WLCS) can become a serious complication of RALP. Here, we report a case of WLCS after RALP. A 75-year-old man underwent surgery for prostate cancer and immediately complained of pain and numbness after surgery. The pressure of the four leg compartments increased. Ultimately, we diagnosed the patient with WLCS in his right leg, and an emergency fasciotomy was performed. He completely recovered with no permanent disability and was discharged one month after rehabilitation. Although WLCS after RALP is a rare and severe complication, the patient recovered completely with early diagnosis and intervention. Measuring the compartment pressure is useful when the patient is drowsy immediately after recovery from anesthesia. Preventing WLCS requires identifying this condition as a potential complication of RALP and all urologic surgeries performed in the lithotomy position. J. Med. Invest. 69 : 145-147, February, 2022.

DOI： 10.2152/jmi.69.145

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: One of the major concerns of patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy is intravesical recurrence (IVR). The purpose of the present study was to investigate the predictive risk factors for IVR after retroperitoneoscopic nephroureterectomy (RNU) for UTUC. METHODS: Clinicopathological and surgical information were collected from the medical records of 73 patients treated with RNU for non-metastatic UTUC, without a history of or concomitant bladder cancer. The association between IVR after RNU and clinicopathological and surgery-related factors, including preoperative urine cytology and pneumoretroperitoneum time, was analyzed using the Fisher exact test. RESULTS: During the median follow-up time of 39.1 months, 18 (24.7%) patients had subsequent IVR after RNU. The 1- and 3-year IVR-free survival rates were 85.9% and 76.5%, respectively. The Fisher exact test revealed that prolonged pneumoretroperitoneum time of ≥ 210 min was a risk factor for IVR in 1 year after RNU (p = 0.0358) and positive urine cytology was a risk factor for IVR in 3 years after RNU (p = 0.0352). CONCLUSIONS: In UTUC, the occurrences of IVR in 1 and 3 years after RNU are highly probable when the pneumoretroperitoneum time is prolonged (≥ 210 min) and in patients with positive urine cytology, respectively. Strict follow-up after RNU is more probable recommended for these patients.

DOI： 10.1186/s12894-021-00932-2

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：日本医科大学医学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wolters Kluwer Medknow Publications  

Purpose: Eligibility for clinical trials is very strict and only patients who satisfy various criteria can enter trials. The individual use of pazopanib has not been adequately investigated. An optimal administration regimen for pazopanib in “real-world” patients with metastatic renal cell carcinoma (mRCC) is required. Our purpose was to determine the tolerability and efficacy of first-line pazopanib with a low starting dose in patients with mRCC who were ineligible for clinical trials. Materials and Methods: This study included patients with mRCC who underwent treatment with first-line pazopanib and were previously excluded from clinical trials because they did not meet the inclusion criteria. A 400 mg pazopanib starting dose is used routinely in patients with mRCC
if tolerated, dose escalation up to 800 mg may occur. Results: We identified 18 patients with mRCC who received first-line pazopanib and were previously determined ineligible for clinical trials. Pazopanib dose was escalated in 12 patients (66.6%), to 600 mg/day in 8 patients (44.4%) and to 800 mg/day in 4 patients (22.2%), and was not escalated in 6 patients (33.3%). In 3 patients (16.7%), pazopanib was discontinued owing to intolerability. The most common frequent adverse event was elevated alanine aminotransferase levels in 6 patients (33.3%), followed by a decreased platelet count in 5 patients (27.8%) and anorexia in 5 patients (27.8%). Partial response was seen in 5 patients (27.8%) and stable disease in 10 patients (55.6%)
median progression-free survival was 11.9 months (95% confidence interval: 6.3–28.7 months). Conclusion: Our data indicated that a low starting dose of 400 mg pazopanib did not negatively affect treatment tolerability and efficacy in patients with mRCC ineligible for clinical trials. We found that lower starting doses may lead to better results. Additional studies are needed in a larger cohort and longer follow-up to attain authentic outcomes.

DOI： 10.4103/UROS.UROS_145_20

Scopus

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

INTRODUCTION: We encountered an extremely rare case of a nephrostomy catheter entering the right renal vein during an exchange procedure. CASE PRESENTATION: An 80-year-old man underwent radical cystectomy. Urinary diversion was achieved through right percutaneous nephrostomy. After the 15th nephrostomy catheter exchange, the patient bled heavily from the catheter. We clamped the catheter immediately, and the patient became hemodynamically stable. Emergency angiography showed the nephrostomy catheter entering the renal vein from outside the renal pelvis. Under fluoroscopy, we pulled the catheter until its tip was located in the previous penetration site of the renal pelvic wall and inserted the catheter over the guidewire into the renal pelvis. CONCLUSIONS: Herein, we report an extremely rare case of a nephrostomy catheter inserted into the right renal vein during an exchange procedure. Inserting a nephrostomy catheter in the appropriate position and performing exchange under imaging guidance techniques could help clinicians avoid severe complications.

DOI： 10.1002/iju5.12276

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/iju5.12276

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：日本医科大学医学会  

82歳。ペットボトルによる自慰後に陰茎がペットボトルの口から抜けなくなり、発熱、陰茎腫脹をきたした。前医にて陰茎絞扼症による尿閉の診断で膀胱瘻造設が行われた。陰茎根部から腹壁にかかる皮膚壊死、尿道損傷、敗血症の合併を認め、緊急陰茎全摘術後に複数回のデブリードマン、残存尿道摘除、抗生剤投与を行った。初診より12ヵ月経過現在、経過良好である。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J04260&link_issn=&doc_id=20210301380004&doc_link_id=%2Fcw1nimed%2F2021%2F001701%2F005%2F0021-0024%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcw1nimed%2F2021%2F001701%2F005%2F0021-0024%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

記述言語：日本語   出版者・発行元：日本医科大学医学会  

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J04260&link_issn=&doc_id=20210301380004&doc_link_id=10.1272%2Fmanms.17.21&url=https%3A%2F%2Fdoi.org%2F10.1272%2Fmanms.17.21&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Transrectal ultrasonography (TRUS)-guided prostate biopsy is the conventional method of diagnosing prostate cancer. TRUS-guided prostate biopsy can occasionally be associated with severe complications. Here, we report the first case of a prostate abscess with aneurysms and spondylodiscitis as a complication of TRUS-guided prostate biopsy, and we review the relevant literature. CASE PRESENTATION: A 78-year-old man presented with back pain, sepsis, and prostate abscesses. Twenty days after TRUS-guided prostate biopsy, he was found to have a 20-mm diameter abdominal aortic aneurysm that expanded to 28.2 mm in the space of a week, despite antibiotic therapy. Therefore, he underwent transurethral resection of the prostate to control prostatic abscesses. Although his aneurysm decreased to 23 mm in size after surgery, he continued to experience back pain. He was diagnosed as having pyogenic spondylitis and this was managed using a lumbar corset. Sixty-four days after the prostate biopsy, the aneurysm had re-expanded to 30 mm; therefore, we performed endovascular aneurysm repair (EVAR) using a microcore stent graft 82 days after the biopsy. Four days after the EVAR, the patient developed acute cholecystitis, and he underwent endoscopic retrograde biliary drainage. One hundred and sixty days after the prostate biopsy, all the complications had improved, and he was discharged. A literature review identified a further six cases of spondylodiscitis that had occurred after transrectal ultrasound-guided prostate biopsy. CONCLUSIONS: We have reported the first case of a complication of TRUS-guided prostate biopsy that involved prostatic abscesses, aneurysms, and spondylodiscitis. Although such complications are uncommon, clinicians should be aware of the potential for such severe complications of this procedure to develop.

DOI： 10.1186/s12894-021-00780-0

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Laparoscopic radical nephrectomy (LRN) is the standard surgical treatment for localized renal cell carcinoma. LRN can be performed using a transperitoneal or retroperitoneal approach. We report a case of a complication specific to the retroperitoneal approach. A 63-year-old woman with localized right renal cell carcinoma was treated with retroperitoneal LRN. During placement of the first port, tumor vessels were damaged by a balloon dilator. Massive hemorrhage from the retroperitoneal cavity required conversion to retroperitoneal laparotomy to stop the bleeding. When laparotomy was performed, active bleeding had already ceased. The bleeding was caused by damage to the tumor vessels from the balloon dilator. Subsequent nephrectomy was performed without other complications. This case suggests that the transperitoneal approach is safer than the retroperitoneal approach when a tumor is located laterally and contains many tumor vessels.

DOI： 10.1272/jnms.JNMS.2021_88-412

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：University of Tokushima Faculty of Medicine  

Hem-o-lok clips are commonly used for renal artery ligation in laparoscopic renal surgery. However, failure of the renal artery ligation clips is potentially fatal. A 61-year-old man underwent hand-assisted laparoscopic nephroureterectomy using a retroperitoneal approach for left ureteral carcinoma. One hour postoperatively, he was diagnosed with hemorrhagic shock. An immediate laparotomy revealed two closed, undamaged Hem-o-lok clips around the left renal artery. Pulsatile bleeding was observed, and the renal artery was immediately ligated with non-absorbable thread. We determined that the failure of the Hem-o-lok clips on the renal artery was caused by the lack of space between the two Hem-o-lok clips and the distal renal artery cuff beyond the distal clip. To prevent a potentially fatal failure of the renal artery ligation clips, one should maintain a sufficient space between the Hem-o-lok clips and an adequate distal renal artery cuff beyond the distal clip. J. Med. Invest. 68 : 393-395, August, 2021.

DOI： 10.2152/jmi.68.393

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：日本医科大学医学会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Plasmacytoid urothelial carcinoma (PUC) of the urinary bladder is a variant of urothelial carcinoma that carries a poor prognosis. The epithelial-mesenchymal transition (EMT) has been demonstrated to contribute to tumor progression. As the cause of the increased aggressiveness of PUC is unknown, we investigated PUC and EMT-related marker expression. METHODS: A total of 633 bladder carcinoma cases diagnosed from 2006 to 2015 at the Nippon Medical School Hospital were analyzed. Twelve patients were found to have plasmacytoid histology and diagnosed with PUC. Slides were evaluated for percentage of plasmacytoid variant, and stained for E-cadherin, N-cadherin, Vimentin, Fibronectin and Snail expression. RESULTS: The incidence of PUC was 1.9% (12/633). The median patient age at diagnosis was 71 years (range, 60-80 years) and the male-female ratio was 11:1. All but three patients had stage T2b or higher. The median overall survival was 10 months. In 10/12 cases, Snail and N-cadherin were positive. Vimentin was positive in 9/12 cases. Fibronectin was positive in 8/12 cases. While E-cadherin was negative in 10/12 cases. Nine cases showed > 10% plasmacytoid component. Eight of the nine patients (88.9%) with > 10% plasmacytoid component died. CONCLUSIONS: The results indicate that PUC may induce EMT and may be associated with high invasion.

DOI： 10.1186/s12894-020-00641-2

PubMed

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: While high body mass index (BMI) and visceral obesity are reportedly associated with a prolonged duration of laparoscopic radical nephrectomy (LRN) via the transperitoneal approach, factors that might prolong the retroperitoneal approach remain unknown. We therefore investigated factors associated with prolonged LRN using a retroperitoneal approach applied by non-expert surgeons. METHODS: We defined surgeons who were not certified to perform laparoscopic surgery by the Japanese Society of Endourology as non-experts. We retrospectively reviewed the medical records of 59 consecutive patients with renal cell carcinoma treated with LRN using the retroperitoneal approach by non-experts at our hospital between 2014 and 2019. Relationships between surgical duration and age, sex, body mass index, visceral fat area (VFA) and subcutaneous fat area (SFA), laterality and location of the tumor, length of major tumor axis (tumor length), clinical T stage, ipsilateral adrenalectomy and specimen weight were analyzed using Spearman rank correlation coefficients. RESULTS: The surgical duration positively correlated with ipsilateral adrenalectomy (rs = 0.3162, p = 0.0147) and specimen weight (rs = 0.3103, p = 0.0168), but not with BMI (rs = 0.2016, p = 0.1257) or VFA (rs = 0.0185, p = 0.8894). CONCLUSIONS: Factors associated with prolonged LRN via the retroperitoneal approach implemented by non-expert surgeons are ipsilateral adrenalectomy and specimen weight.

DOI： 10.1272/jnms.JNMS.2021_88-302

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

PURPOSE: Bladder endometriosis (BE) is rare. Deep invasive endometriosis is difficult to control with medications alone; such cases need surgical treatment. Good results of laparoscopic partial cystectomy with a transurethral (TU) resectoscope by the see-through technique for patients with BE are reported. MATERIALS AND METHODS: From January 2008 to February 2016, 12 cases of symptomatic BE were seen in our institution. The chief complaints of 9 cases were micturition pain during menstruation. Preoperative cystoscopy showed a bladder mass with blueberry spots. All surgeries were performed under general anesthesia. Laparoscopic surgery was performed with a fan of 4 ports in the lower abdomen. First, the uterus and bilateral ovaries were checked. Then, the TU resectoscope was inserted. When the affected bladder wall was identified, it was again observed with the laparoscopic light source off, which made it possible to observe the twilight leaking inside from the bladder. This twilight came from the light source of the TU resectoscope via the unaffected bladder wall. In contrast, the thickness of the affected wall prevented the light from inside the bladder from passing through it. We call this the "see-through technique." The tumor was then safely dissected with both laparoscopic and TU resection procedures. Finally, the bladder was sutured by laparoscopic procedures using absorbable sterile surgical suture. The urethral catheter was removed after cystography 7 days after the operation. RESULTS: The surgical margins of all cases were negative. There has been no recurrence of BE so far in any patients. There were no major adverse events perioperatively and the urinary symptoms improved in all cases. CONCLUSIONS: By laparoscopic partial cystectomy assisted with a TU resectoscope and see-through technique, the edge of BE could be easily and precisely identified. These procedures are effective and safe for BE surgical treatment.

DOI： 10.1159/000503795

PubMed

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

The lipid cell variant of urethral carcinoma (UC) is rare and poorly understood clinicopathologically. A nodular tumor detected in the bladder of an 87-year-old man with asymptomatic gross hematuria was transurethrally resected, and high-grade UC, lipid cell variant, was diagnosed pathologically. The tumor cells resembled lipoblasts and contained numerous cytoplasmic vacuoles. Immunohistochemically, the tumor cells stained positive for the epithelial markers CK7, CK20, EMA, CAM5.2, and 34betaE12 and negative for vimentin and S100. Focal positivity for adipophilin was detected in cytoplasm but not in the vacuoles. These findings suggest that the patient had lipid-producing UC.

DOI： 10.1272/jnms.JNMS.2019_86-602

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本皮膚科学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Background: Various devices for isolating and detecting circulating tumor cells (CTCs) have been developed, whereas the CellSearch® system has been clinically used in numerous prostate CTC studies. CTCs might become more useful surrogate markers of prostate cancer, and they should be measured in all settings, but a smaller, low-cost CTC capture system is required. Methods: An inexpensive and highly sensitive microfluidic CTC-capture polymeric chip, developed by the Toyama Industrial Technology Center, as described in the following text, was used to assess the number of CTCs from patients with metastatic prostate cancer. After verifying that cultured human prostate cancer cells (PC3 and LNCaP) could be captured with the chip coated with anti-epithelial cell adhesion molecule (CD326) antibody, whole blood samples of 14 patients with prostate cancer were screened. Results: The average capture efficacy of PC3 cells was 94.60% in phosphate-buffered saline (PBS) and 83.82% in whole blood. The average capture efficacy of LNCaP cells was 82.73% in PBS and 75.78% in whole blood. CTCs were detected by the chip device in all 14 patients with metastatic prostate cancer using 2-mL blood samples. Although fewer CTCs were detected in patients with oligometastases, all patients with multiple distant metastases had CTCs. The average CTC count was 48 cells/mL (range 1-81 cells/mL). Conclusion: This CTC-chip will be able to capture CTCs and be useful to check CTCs as a surrogate marker in prostate cancer with smaller samples and lower cost in any small institution.

DOI： 10.1016/j.prnil.2019.01.003

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

Deep learning algorithms have achieved great success in cancer image classification. However, it is imperative to understand the differences between the deep learning and human approaches. Using an explainable model, we aimed to compare the deep learning-focused regions of magnetic resonance (MR) images with cancerous locations identified by radiologists and pathologists. First, 307 prostate MR images were classified using a well-established deep neural network without locational information of cancers. Subsequently, we assessed whether the deep learning-focused regions overlapped the radiologist-identified targets. Furthermore, pathologists provided histopathological diagnoses on 896 pathological images, and we compared the deep learning-focused regions with the genuine cancer locations through 3D reconstruction of pathological images. The area under the curve (AUC) for MR images classification was sufficiently high (AUC = 0.90, 95% confidence interval 0.87-0.94). Deep learning-focused regions overlapped radiologist-identified targets by 70.5% and pathologist-identified cancer locations by 72.1%. Lymphocyte aggregation and dilated prostatic ducts were observed in non-cancerous regions focused by deep learning. Deep learning algorithms can achieve highly accurate image classification without necessarily identifying radiological targets or cancer locations. Deep learning may find clues that can help a clinical diagnosis even if the cancer is not visible.

DOI： 10.3390/biom9110673

PubMed

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)西日本泌尿器科学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.14601

PubMed

researchmap

記述言語：英語  

DOI： 10.1111/1346-8138.14601

PubMed

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

A 73-year-old man presented with right lower back pain and dysuria. Right hydronephrosis and a large pelvic large mass were seen on computed tomography (CT). Although his prostate-specific antigen (PSA) was 0.5 ng/mL, an irregularly enlarged, stony, hard prostate was palpable on digital rectal examination. A prostate tumor was suspected, and a transrectal prostate biopsy and right transurethral ureteral stent placement were performed. Histological and immunohistochemical studies revealed diffuse large B-cell lymphoma. Positron emission tomography-computed tomography showed abnormal uptake in the stomach, cecum, right obturator lymph nodes, para-aortic lymph nodes, and dorsal left kidney. No abnormal findings were seen on bone marrow histology. Clinical stage IVA was confirmed according to Ann Arbor criteria. The patient achieved a complete response after 8 cycles of combination chemotherapy with rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisolone.

DOI： 10.1272/jnms.JNMS.2018_85-37

PubMed

researchmap

記述言語：日本語   掲載種別：研究論文（学術雑誌）  

DOI： 10.5980/jpnjurol.108.30

PubMed

researchmap

記述言語：日本語   掲載種別：研究論文（学術雑誌）  

PubMed

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

日本医科大学千葉北総病院において非転移性前立腺癌37例に対する内分泌療法併用三次元原体照射放射線療法の治療結果を検討した。PSA nadirは1例を除き0.2ng/ml未満に低下し、5年PSA非再発率は87.9%、5年癌特異的生存率は97.0%であった。Grade3以上の有害事象は1例も認めなかった。(著者抄録)

researchmap

記述言語：日本語   掲載種別：研究論文（学術雑誌）  

PubMed

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

researchmap

記述言語：日本語   掲載種別：研究論文（学術雑誌）  

PubMed

researchmap

記述言語：日本語   出版者・発行元：一般社団法人 日本泌尿器科学会  

DOI： 10.5980/jpnjurol.102.491_1

researchmap

記述言語：日本語   出版者・発行元：一般社団法人 日本泌尿器科学会  

DOI： 10.5980/jpnjurol.102.452_2

researchmap

記述言語：日本語   出版者・発行元：一般社団法人 日本泌尿器科学会  

DOI： 10.5980/jpnjurol.102.517_1

researchmap

記述言語：日本語   掲載種別：研究論文（学術雑誌）  

PubMed

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：LIPPINCOTT WILLIAMS & WILKINS  

DOI： 10.1200/JCO.2022.40.6_suppl.453

Web of Science

researchmap

記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：LIPPINCOTT WILLIAMS & WILKINS  

DOI： 10.1200/JCO.2022.40.6_suppl.555

Web of Science

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：LIPPINCOTT WILLIAMS & WILKINS  

DOI： 10.1200/JCO.2021.39.6_suppl.473

Web of Science

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：西日本泌尿器科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本毒性学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本毒性学会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：日本外科系連合学会  

膀胱瘻の現状,特に合併症と患者ケアのポイントについて,自験例29例を提示しながら解説した.膀胱瘻の原因は全国的には神経因性膀胱が最も多いが,一般病院では著者らの集計のように尿道狭窄が最も多く(37.9%),神経因性膀胱(27.6%)がそれに次ぐ.膀胱瘻は尿路感染症や腎機能障害など生命予後に影響する合併症の頻度は低く,経皮的造設による膀胱瘻は有用な尿路変更法と考えられる.しかし,今後高齢者および在宅医療の増加が見込まれるにもかかわらず,不意なカテーテルの抜去など患者ケアの対応が確立されていないのが現状で,カテーテルの抜去時に高齢者用の施設のほとんどで看護師が夜間いないため翌日病院を受診する際は膀胱瘻が閉鎖され余分なマンパワーを必要とすることが少なくない.まずは不必要な再度の経皮的膀胱瘻造設術を避けるために患者または家族が直ちにカテーテルを挿入し膀胱瘻の道を確保できるよう,8F程度の細いカテーテルを患者に渡しておく配慮は極めて有用と思われた.(著者抄録)

researchmap

記述言語：日本語   出版者・発行元：(公社)日本薬学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡学会  

researchmap

記述言語：日本語   出版者・発行元：西日本泌尿器科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本生化学会  

researchmap

記述言語：日本語   出版者・発行元：(有)科学評論社  

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2016375270

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：腎癌研究会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：日本外科系連合学会  

近年,前立腺全摘術に関する論文は鏡視下およびロボット支援手術がほとんどであるが,術中開腹手術への移行に備えて開腹前立腺全摘術の高等な技術をレジデントのうちに習得しておくことは必要である.今回那須赤十字病院において,経験の少ない(泌尿器科経験平均3年程度)医師3人と1人の指導者のもと,64例の開腹前立腺全摘術を施行したので,治療成績について検討した.平均手術時間は261分,平均出血量は1,270mlで全例自己血800mlを用意し使用し,1例のみ自己血以外に同種血輸血を必要とした.断端陽性率は64例中4例(6.25%)で,平均観察期間32.0ヵ月でPSA再発は2例(3.1%)に認められた.パッドフリー症例は51症例(79.7%)であった.泌尿器科経験3年程度の術者が施行した開腹前立腺全摘術では,術中侵襲がやや大きいが,癌制御と機能温存の点では良好であった.(著者抄録)

DOI： 10.4030/jjcs.41.152

researchmap

記述言語：日本語   出版者・発行元：日本外科系連合学会  

高齢者,特に85歳以上の超高齢者は合併症や全身状態を考慮すると,薬物療法抵抗性の排尿障害に対する経尿道的前立腺切除術(TURP)は議論がある.よって今回われわれは薬物療法抵抗性の排尿障害を有する超高齢者に対するTURPの有効性と安全性について検討した.対象は8症例で,平均年齢90歳であった.全例腰椎麻酔下でTURPを施行.平均手術時間は61分,平均前立腺切除重量は25g,輸血症例は2症例であった.全例において術中,術後の合併症はなく,術後カテーテル抜去が可能となった.また平均観察期間37.6ヵ月においても全例でカテーテルは留置されていない.以上より麻酔可能である場合の超高齢患者において,投薬にてカテーテルが抜去できない場合は有効性と安全性の面からTURPは検討してよい治療法と思われた.(著者抄録)

DOI： 10.4030/jjcs.41.147

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：日本外科系連合学会  

外傷性会陰部膿瘍,特に巨大なものは珍しい.43歳男性が会陰部の腫脹・疼痛を訴え当院救急外来を受診した.患者は24日前に橋から川に転倒し背部と臀部を強打した.同日,近医を受診し,腰椎横突起骨折・臀部打撲の診断を受けた.鎮痛剤が処方され背部痛は軽快したが,会陰部痛は徐々に増強したため当院救急外来を受診した.MRIにて11×6×6cmの会陰部膿瘍を認めたため,直ちに会陰部を縦切開し血性膿液を除去しデブリドマンを施行した.創部からの分泌物の細菌培養でEnterobacter aerogenes,Staphylococcus epidermisが検出された.Cefotiamを10日間静脈投与後,ST合剤の経口投与に変更した.開放創を連日生理食塩水で洗浄し,ポビドンヨードシュガーを創部に投与した.本薬剤は感染のある創,浸出液の多い創に有用で,今回の創はそれに合致する状態であった.しかし創部の状況を評価することなく病院に長く居たいとの患者の希望があったため第53病日に退院となった.外傷に起因した会陰部膿瘍は極めて稀でありわれわれの検索した限りでは,過去50年間本邦報告例はなかった.このような症例の報告は本誌の特性から,泌尿器科以外の他科に知ってもらうことは有用ではないかと考え報告する.(著者抄録)

DOI： 10.4030/jjcs.41.244

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2016&ichushi_jid=J01066&link_issn=&doc_id=20160520150019&doc_link_id=10.4030%2Fjjcs.41.244&url=https%3A%2F%2Fdoi.org%2F10.4030%2Fjjcs.41.244&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：AMER SOC CLINICAL ONCOLOGY  

Web of Science

researchmap

J-GLOBAL

researchmap

記述言語：日本語   出版者・発行元：(株)医学書院  

浸潤性膀胱がんに対する根治治療として膀胱全摘術は確立されているが,膀胱全摘術後の再発率は50%前後であり,まだまだ十分なものとは言い難い。術後の局所再発・遠隔転移に対しては化学療法が行われており,シスプラチンがキードラッグとなっている。周術期化学療法については,術前化学療法の有効性が示され,術後化学療法においても確立しつつある。全身化学療法については,一次化学療法は確立されているが,二次化学療法は確立されていない。そのような状況のなかで新規保険適用薬が増え,選択肢の幅が増えた。また,新規分子標的薬の有効性が期待されており,動向が期待される分野である。(著者抄録)

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2016042107

記述言語：日本語   出版者・発行元：(一社)日本核医学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(有)科学評論社  

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/2015342021

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会総会事務局  

researchmap

記述言語：日本語   出版者・発行元：日本尿路結石症学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡学会  

researchmap

記述言語：日本語   出版者・発行元：泌尿器科紀要刊行会  

48歳女。尿失禁を主訴とした。約半年前に子宮頸癌に対し広汎子宮全摘術および骨盤内放射線照射を受けていた。膀胱造影で膀胱三角部に長軸約3cmの瘻孔を認め、膀胱腟瘻と診断し経腹膀胱腟瘻閉鎖術を施行した。しかし、帝王切開および広汎子宮全摘術の既往から腹膜も大網も利用できず、修復術は不成功に終わった。また、術中に小腸の骨盤壁への強固な癒着から小腸損傷が生じ、回腸人工肛門の造設を余儀なくされた。術後13ヵ月に2回目の膀胱腟瘻閉鎖術を施行し、手術は形成外科医の強力を得て、腹直筋皮弁を用いた修復術を行った。術後18日に膀胱造影で尿漏れがないことを確認し、膀胱留置カテーテルを抜去した。その後、尿失禁はなく、術後23日に退院し、術後15ヵ月現在まで再発を認めていない。また、患者の希望で回腸人工肛門の修復は行われていない。

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J01269&link_issn=&doc_id=20141110440007&doc_link_id=120005511056&url=http%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F120005511056&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

記述言語：日本語   出版者・発行元：日本尿路結石症学会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

(目的)今回我々はTAEが深在性腎損傷に対し有用であるか、またその有用性が病院の規模で差があるか否かを検討した。(対象と方法)2001年4月から2011年4月までの日本医科大学付属病院の腎損傷42例、2001年4月から2009年4月までの大田原赤十字病院の腎損傷33例を対象とした。腎損傷分類はCTと術中所見をもとに2008年の日本外傷学会分類に準じ、主に治療法について検討した。(結果)日本医科大学付属病院42例は平均41.6歳、男性36例、女性6例、分類はI型16例、II型11例、III型15例であった。治療は保存的30例、TAE7例、手術5例で、TAE・手術はIII型に対し行われた。42例中5例死亡したが腎損傷単独の死亡例はなかった。一方大田原赤十字病院33例は平均46.6歳、男性25例、女性8例、分類はI型9例、II型12例、III型12例であった。治療は保存的24例、TAE9例、手術症例はなく、TAEはII型1例とIII型8例に行われた。33例中8例死亡したが、腎損傷単独の死亡例はなかった。両施設でTAEは16例行われ、15例はIII型でありTAEが得られなければ腎摘をした可能性があり、TAEの有用性が確認された。(結論)病院規模によらずIII型に対してTAEが多く行われており手術症例を減らす上でもTAEは有用である。(著者抄録)

researchmap

記述言語：日本語   出版者・発行元：日本尿路結石症学会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：英語   掲載種別：研究発表ペーパー・要旨（国際会議）   出版者・発行元：ELSEVIER SCIENCE INC  

Web of Science

researchmap

記述言語：日本語   出版者・発行元：THE JAPANESE UROLOGICAL ASSOCIATION  

(目的) 今回我々はTAEが深在性腎損傷に対し有用であるか，またその有用性が病院の規模で差があるか否かを検討した． (対象と方法) 2001年4月から2011年4月までの日本医科大学付属病院の腎損傷42例，2001年4月から2009年4月までの大田原赤十字病院の腎損傷33例を対象とした．腎損傷分類はCTと術中所見をもとに2008年の日本外傷学会分類に準じ，主に治療法について検討した． (結果) 日本医科大学付属病院42例は平均41.6歳，男性36例，女性6例，分類はI型16例，II型11例，III型15例であった．治療は保存的30例，TAE 7例，手術5例で，TAE・手術はIII型に対し行われた．42例中5例死亡したが腎損傷単独の死亡例はなかった．一方大田原赤十字病院33例は平均46.6歳，男性25例，女性8例，分類はI型9例，II型12例，III型12例であった．治療は保存的24例，TAE 9例，手術症例はなく，TAEはII型1例とIII型8例に行われた．33例中8例死亡したが，腎損傷単独の死亡例はなかった．両施設でTAEは16例行われ，15例はIII型でありTAEが得られなければ腎摘をした可能性があり，TAEの有用性が確認された． (結論) 病院規模によらずIII型に対してTAEが多く行われており手術症例を減らす上でもTAEは有用である．

DOI： 10.5980/jpnjurol.104.688

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡学会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：日本尿路結石症学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

DOI： 10.5980/jpnjurol.102.560_6

researchmap

記述言語：日本語   出版者・発行元：一般社団法人 日本泌尿器科学会  

DOI： 10.5980/jpnjurol.102.563_1

researchmap

記述言語：日本語   出版者・発行元：(一社)日本排尿機能学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

DOI： 10.5980/jpnjurol.101.262_3

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器科学会  

50歳、男性。2ヵ月前より疼痛を伴った両側陰嚢内腫瘤を認めたため当科受診。両側精巣上体炎を疑い、2週間抗生剤と鎮痛剤を投与したが無効であった。陰嚢エコーにて陰嚢内の悪性腫瘍も否定できないため高位左精巣摘除術施行。病理組織学的所見にて壊死性血管炎を認め、結節性多発動脈炎の診断となり、当院リウマチ科において精査施行。結節性多発動脈炎における全身症状や血液免疫学的検査に異常を認めないことより、精巣上体発症の局所性結節性多発動脈炎と診断された。対側に対してはステロイド療法を勧めたが、陰嚢内の疼痛が強いため患者が強く外科的治療による早急な症状改善を希望したため、対側に対しても高位精巣摘除術を施行。病理組織学的所見は左側同様に結節性多発動脈炎であった。術後自覚症状は消失し、術後2年経過した現在再発等は認めていない。文献的検索では、両側陰嚢内発症の局所性結節性多発動脈炎は第一例である。(著者抄録)

DOI： 10.5980/jpnjurol.101.570

Scopus

researchmap

記述言語：日本語   出版者・発行元：一般社団法人 日本泌尿器科学会  

DOI： 10.5980/jpnjurol.101.258_1

researchmap

記述言語：日本語   出版者・発行元：一般社団法人 日本泌尿器科学会  

DOI： 10.5980/jpnjurol.101.524_2

researchmap

記述言語：日本語   出版者・発行元：一般社団法人 日本泌尿器科学会  

DOI： 10.5980/jpnjurol.101.408_3

researchmap

記述言語：日本語   出版者・発行元：(一社)日本泌尿器内視鏡学会  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

記述言語：日本語   出版者・発行元：医学図書出版(株)  

researchmap

開催年月日： 2019年2月

記述言語：英語   会議種別：ポスター発表  

添付ファイル： 2019.2 ASCO-GU poster ENNDO-OUT最終.pdf

researchmap

記述言語：英語  

researchmap

記述言語：英語   会議種別：口頭発表（一般）  

researchmap